Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
18 Leser
Artikel bewerten:
(0)

Global Discovery Stage Partnering Deals and Agreements Analysis Report 2010-2017

DUBLIN, August 24, 2017 /PRNewswire/ --

The "Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010- 2017" report has been added to Research and Markets' offering.

Research and Markets Logo

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2010 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties.


Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017 include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2010
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 3,000 discovery stage deals
  • The leading discovery stage deals by value since 2010
  • Most active discovery stage dealmakers since 2010
  • The leading discovery stage partnering 2010

The available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

Chapter 3 - Discovery stage deal strategies and structure

Chapter 4 - Discovery stage partnering payment strategies

Chapter 5 - Trends in discovery stage deal making

Chapter 6 - Payment terms for discovery stage partnering

Chapter 7 - Leading discovery stage deals

Chapter 8 - Top 50 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

Chapter 10 - Discovery stage deal making by development stage

For more information about this report visit https://www.researchandmarkets.com/research/6wlg8q/global_discovery


Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.